Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 12, 2007
- Asahi Kasei Pharma: Sales, Operating Profits Up 7.4%
November 12, 2007
- Strong Opposition to "Financial Adjustment" between Health Insurance Programs
November 12, 2007
- Teijin Pharma: Drugs for Osteoporosis Prop Up Sales
November 12, 2007
- Korosho Calls For Fairer Reward for Innovative New Drugs
November 12, 2007
- Torii: Anti-HIV Drugs Show Strong Growth in Sales
November 12, 2007
- US FDA Requests Additional Clinical Data on TAK-475: Takeda
November 12, 2007
- Kyowa Hakko Kogyo: Pharma Sales Up 5.8% to \68,900 Mil.
November 12, 2007
- All Antidepressants to Warn of Risk of Suicide in Patients Aged 24 or Younger
November 12, 2007
- Former Tanabe Seiyaku: Remicade Drives Sales, Profits
November 12, 2007
- Concerta Approved for ADHD, Depression Deleted as Indication for Ritalin
November 12, 2007
- Eisai: Record-High Sales, Profits Driven by Aricept
November 12, 2007
- JMA Calls For Reimbursement of Generics Used Off-label
November 12, 2007
- Debiopharm Licenses DACH-platin MediCelle from NanoCarrier
November 12, 2007
- Sawai Revises Business Forecasts Downward
November 12, 2007
- Taisho Concludes LOI with Pfizer on TS-032
November 12, 2007
- Korosho Proposes Revisions of NHI Pricing Rules
November 5, 2007
- J-TEC Aims at \1 Bil. with Japan's First Cultured Autologous Epidermis
November 5, 2007
- Conclusion Not yet Drawn on Causal Relation between Tamiflu and Abnormal Behavior
November 5, 2007
- Korosho Proposes More Fees for Treatment of Mental Illness
November 5, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…